TY - JOUR
T1 - Opinion review of drug resistant tuberculosis in West Africa
T2 - tackling the challenges for effective control
AU - Otchere, Isaac Darko
AU - Asante-Poku, Adwoa
AU - Akpadja, Kodjo Francis
AU - Diallo, Awa Ba
AU - Sanou, Adama
AU - Asare, Prince
AU - Osei-Wusu, Stephen
AU - Onyejepu, Nneka
AU - Diarra, Bassirou
AU - Dagnra, Yaotsè Anoumou
AU - Kehinde, Aderemi
AU - Antonio, Martin
AU - Yeboah-Manu, Dorothy
N1 - Publisher Copyright:
Copyright © 2024 Otchere, Asante-Poku, Akpadja, Diallo, Sanou, Asare, Osei-Wusu, Onyejepu, Diarra, Dagnra, Kehinde, Antonio and Yeboah-Manu.
PY - 2024
Y1 - 2024
N2 - Drug-resistant (DR) tuberculosis (TB) is a major public health concern globally, complicating TB control and management efforts. West Africa has historically faced difficulty in combating DR-TB due to limited diagnostic skills, insufficient access to excellent healthcare, and ineffective healthcare systems. This has aided in the emergence and dissemination of DR Mycobacterium tuberculosis complex (MTBC) strains in the region. In the past, DR-TB patients faced insufficient resources, fragmented efforts, and suboptimal treatment outcomes. However, current efforts to combat DR-TB in the region are promising. These efforts include strengthening diagnostic capacities, improving access to quality healthcare services, and implementing evidence-based treatment regimens for DR-TB. Additionally, many West African National TB control programs are collaborating with international partners to scale up laboratory infrastructure, enhance surveillance systems, and promote infection control measures. Moreso, novel TB drugs and regimens, such as bedaquiline and delamanid, are being introduced to improve treatment outcomes for DR-TB cases. Despite these obstacles, there is optimism for the future of DR-TB control in West Africa. Investments are being made to improve healthcare systems, expand laboratory capacity, and support TB research and innovation. West African institutions are now supporting knowledge sharing, capacity building, and resource mobilization through collaborative initiatives such as the West African Network for TB, AIDS, and Malaria (WANETAM), the West African Health Organization (WAHO), and other regional or global partners. These efforts hold promise for improved diagnostics, optimized treatment regimens, and provide better patient outcomes in the future where drug-resistant TB in WA can be effectively controlled, reducing the burden of the disease, and improving the health outcomes of affected individuals.
AB - Drug-resistant (DR) tuberculosis (TB) is a major public health concern globally, complicating TB control and management efforts. West Africa has historically faced difficulty in combating DR-TB due to limited diagnostic skills, insufficient access to excellent healthcare, and ineffective healthcare systems. This has aided in the emergence and dissemination of DR Mycobacterium tuberculosis complex (MTBC) strains in the region. In the past, DR-TB patients faced insufficient resources, fragmented efforts, and suboptimal treatment outcomes. However, current efforts to combat DR-TB in the region are promising. These efforts include strengthening diagnostic capacities, improving access to quality healthcare services, and implementing evidence-based treatment regimens for DR-TB. Additionally, many West African National TB control programs are collaborating with international partners to scale up laboratory infrastructure, enhance surveillance systems, and promote infection control measures. Moreso, novel TB drugs and regimens, such as bedaquiline and delamanid, are being introduced to improve treatment outcomes for DR-TB cases. Despite these obstacles, there is optimism for the future of DR-TB control in West Africa. Investments are being made to improve healthcare systems, expand laboratory capacity, and support TB research and innovation. West African institutions are now supporting knowledge sharing, capacity building, and resource mobilization through collaborative initiatives such as the West African Network for TB, AIDS, and Malaria (WANETAM), the West African Health Organization (WAHO), and other regional or global partners. These efforts hold promise for improved diagnostics, optimized treatment regimens, and provide better patient outcomes in the future where drug-resistant TB in WA can be effectively controlled, reducing the burden of the disease, and improving the health outcomes of affected individuals.
KW - challenges
KW - collaboration
KW - control measures
KW - drug resistance
KW - tuberculosis
KW - WANETAM
KW - West Africa
UR - http://www.scopus.com/inward/record.url?scp=85194999484&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2024.1374703
DO - 10.3389/fpubh.2024.1374703
M3 - Review article
C2 - 38827613
AN - SCOPUS:85194999484
SN - 2296-2565
VL - 12
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1374703
ER -